Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Drug development

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Introduction In the last 15 years, huge efforts against Alzheimer's disease (AD) with drugs targeting β-amyloid (Aβ) and tau have produced poor clinical results. Aducanumab, a recently FDA-approved anti-Aβ monoclonal antibody has been greeted with distrust by most experts, hospitals and insurance companies for its level of efficacy and poor tolerability. Area covered We reviewed literature on Alzheimer trials using PubMed, meeting abstracts and ClnicalTrials.gov and discuss what we can learn from past failures of investigational drugs for Alzheimer's disease, especially anti-Aβ and anti-tau drugs.

What this study adds

Evidence grade: Low

This is a narrative review. This review of past Alzheimer's drug trials found that 15 years of efforts targeting β-amyloid and tau produced poor clinical results. The authors state that aducanumab, an anti-Aβ antibody, has been met with distrust by most experts, hospitals and insurance companies because of its level of efficacy and poor tolerability.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Imbimbo, B. P., & Watling, M. (2021). What have we learned from past failures of investigational drugs for Alzheimer's disease? Expert opinion on investigational drugs. https://doi.org/10.1080/13543784.2021.2017881

Vancouver

Imbimbo BP, Watling M. What have we learned from past failures of investigational drugs for Alzheimer's disease? Expert opinion on investigational drugs. 2021. doi:10.1080/13543784.2021.2017881. PMID: 34890262.

BibTeX

@article{imbimbo2021-34890262,
  author  = {Imbimbo, B. P. and Watling, M.},
  title   = {{What have we learned from past failures of investigational drugs for Alzheimer's disease?}},
  journal = {Expert opinion on investigational drugs},
  year    = {2021},
  doi     = {10.1080/13543784.2021.2017881},
  pmid    = {34890262},
  url     = {https://doi.org/10.1080/13543784.2021.2017881}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review of past Alzheimer's drug trials found that 15 years of efforts targeting β-amyloid and tau produced poor clinical results. The authors state that aducanumab, an anti-Aβ antibody, has been met with distrust by most experts, hospitals and insurance companies because of its level of efficacy and poor tolerability.

Study details

How this study scored 34/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 34 of 100.34 of 100 points earned66 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Expert opinion on investigational drugs)
Journal's citation record 1 / 4 Expert Opinion on Investigational Drugs: journal h-index 132 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 23 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.3 citations a year over 7 year(s) since 2021
Impact for its field and year 2 / 6 Cited 2.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Mark I L Watling: h-index 21 (OpenAlex, whole career)
Institution's track record 0 / 3 Chiesi (Italy): institution h-index 115 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 34890262)
Free to read 0 / 2 Behind a paywall — scores zero
Total 34 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Related studies in Drug development from nearby years

Also in Drug development

104 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.

Similar studies

More on Drug development

See all studies in Drug development →